These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7517880)

  • 1. CHF 2206, a new potent vasodilating and antiaggregating drug as potential nitric oxide donor.
    Civelli M; Caruso P; Giossi M; Bergamaschi M; Razzetti R; Bongrani S; Gasco A
    Eur J Pharmacol; 1994 Apr; 255(1-3):17-24. PubMed ID: 7517880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The involvement of the release of nitric oxide in the pharmacological activity of the new furoxan derivative CHF 2363.
    Civelli M; Giossi M; Caruso P; Razzetti R; Bergamaschi M; Bongrani S; Gasco A
    Br J Pharmacol; 1996 Jun; 118(4):923-8. PubMed ID: 8799563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of oxyhaemoglobin to explore the events underlying inhibition of platelet aggregation induced by NO or NO-donors.
    Salvemini D; Radziszewski W; Korbut R; Vane J
    Br J Pharmacol; 1990 Dec; 101(4):991-5. PubMed ID: 1707709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasorelaxant and antiplatelet activity of 4,7-dimethyl-1,2, 5-oxadiazolo[3,4-d]pyridazine 1,5,6-trioxide: role of soluble guanylate cyclase, nitric oxide and thiols.
    Kots AY; Grafov MA; Khropov YV; Betin VL; Belushkina NN; Busygina OG; Yazykova MY; Ovchinnikov IV; Kulikov AS; Makhova NN; Medvedeva NA; Bulargina TV; Severina IS
    Br J Pharmacol; 2000 Mar; 129(6):1163-77. PubMed ID: 10725265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No-mimetic furoxans: arylsulphonylfuroxans and related compounds.
    Ferioli R; Fazzini A; Folco GC; Fruttero R; Calvino R; Gasco A; Bongrani S; Civelli M
    Pharmacol Res; 1993; 28(3):203-12. PubMed ID: 8108310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on inhibition of human platelet function by sodium nitroprusside. Kinetic evaluation of the effect on aggregation and cyclic nucleotide content.
    Anfossi G; Russo I; Massucco P; Mattiello L; Balbo A; Cavalot F; Trovati M
    Thromb Res; 2001 May; 102(4):319-30. PubMed ID: 11369425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Organic nitrates and compounds that increase intraplatelet cyclic guanosine monophosphate (cGMP) levels enhance the antiaggregating effects of the stable prostacyclin analogue iloprost.
    Anfossi G; Massucco P; Mularoni E; Cavalot F; Mattiello L; Trovati M
    Prostaglandins Leukot Essent Fatty Acids; 1993 Nov; 49(5):839-45. PubMed ID: 7508131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular and anti-platelet actions of 1,2- and 1,3-glyceryl dinitrate.
    Salvemini D; Pistelli A; Anggard E
    Br J Pharmacol; 1993 Nov; 110(3):937-42. PubMed ID: 8298817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new class of furoxan derivatives as NO donors: mechanism of action and biological activity.
    Ferioli R; Folco GC; Ferretti C; Gasco AM; Medana C; Fruttero R; Civelli M; Gasco A
    Br J Pharmacol; 1995 Feb; 114(4):816-20. PubMed ID: 7773542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin increases guanosine-3',5'-cyclic monophosphate in human platelets. A mechanism involved in the insulin anti-aggregating effect.
    Trovati M; Massucco P; Mattiello L; Mularoni E; Cavalot F; Anfossi G
    Diabetes; 1994 Aug; 43(8):1015-9. PubMed ID: 7518780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion of glyceryl trinitrate to nitric oxide in tolerant and non-tolerant smooth muscle and endothelial cells.
    Salvemini D; Pistelli A; Vane J
    Br J Pharmacol; 1993 Jan; 108(1):162-9. PubMed ID: 8381319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside.
    Negrescu EV; Grünberg B; Kratzer MA; Lorenz R; Siess W
    Cardiovasc Drugs Ther; 1995 Aug; 9(4):619-29. PubMed ID: 8547213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A xanthine-based KMUP-1 with cyclic GMP enhancing and K(+) channels opening activities in rat aortic smooth muscle.
    Wu BN; Lin RJ; Lin CY; Shen KP; Chiang LC; Chen IJ
    Br J Pharmacol; 2001 Sep; 134(2):265-74. PubMed ID: 11564644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
    Maurice DH; Haslam RJ
    Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LY 83583 (6-anilino-5,8-quinolinedione) blocks nitrovasodilator-induced cyclic GMP increases and inhibition of platelet activation.
    Mülsch A; Lückhoff A; Pohl U; Busse R; Bassenge E
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Jul; 340(1):119-25. PubMed ID: 2552329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity.
    Galle J; Zabel U; Hübner U; Hatzelmann A; Wagner B; Wanner C; Schmidt HH
    Br J Pharmacol; 1999 May; 127(1):195-203. PubMed ID: 10369473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosine increases human platelet levels of cGMP through nitric oxide: possible role in its antiaggregating effect.
    Anfossi G; Russo I; Massucco P; Mattiello L; Cavalot F; Balbo A; Trovati M
    Thromb Res; 2002 Jan; 105(1):71-8. PubMed ID: 11864710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet inhibition by an L-arginine-derived substance released by IL-1 beta-treated vascular smooth muscle cells.
    Durante W; Schini VB; Scott-Burden T; Junquero DC; Kroll MH; Vanhoutte PM; Schafer AI
    Am J Physiol; 1991 Dec; 261(6 Pt 2):H2024-30. PubMed ID: 1661096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacochemistry of the furoxan ring: recent developments.
    Calvino R; Di Stilo A; Fruttero R; Gasco AM; Sorba G; Gasco A
    Farmaco; 1993 Feb; 48(2):321-34. PubMed ID: 8388218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of inorganic nitrate and nitrite in driving nitric oxide-cGMP-mediated inhibition of platelet aggregation in vitro and in vivo.
    Apostoli GL; Solomon A; Smallwood MJ; Winyard PG; Emerson M
    J Thromb Haemost; 2014 Nov; 12(11):1880-9. PubMed ID: 25163536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.